[A26-41] Pembrolizumab (head and neck squamous cell carcinoma, neoadjuvant and adjuvant) – Addendum to Project A25-148
Last updated 21.05.2026
Project no.:
A26-41
Commission:
Commission awarded on 08.04.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumours express programmed death-ligand 1 with a combined positive score ≥ 1
- Patients with a high postoperative risk profile for whom cisplatin-based therapy is suitable, or with a low postoperative risk profile; neoadjuvant and adjuvant therapy: unchanged after addendum: hint of a minor added benefit
- Patients with a high postoperative risk profile for whom cisplatin-based therapy is not suitable; neoadjuvant and adjuvant therapy: unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A26-41
| Project no. | Title | Status |
|---|---|---|
| A25-148 | Pembrolizumab (head and neck squamous cell carcinoma) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
21-05-2026 A G-BA decision was published.
G-BA documents on this decision